BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VQPH) announced today that the following preclinical abstracts involving the Company’s product candidate VQD-002 (triciribine phosphate monohydrate, or TCN-P, also referred to as API-2) are expected to be the subject of oral or poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:
